Europe’s Regional Premier Biologics Manufacturing & Contract Manufacturing Conference for the Biopharma Community
Catch the Latest Innovations Driving the Europe's Biologics Industry
14th-15th June 2023 | Frankfurt, Germany
0+
Attendees
0+
Companies
0+
Speakers
0+
In-Person Networking Hours
0+
Case Studies
The Concept
Biologics Manufacturing Europe 2023 is the European region’s premier conference for the manufacturing community. This event connects the leaders of Biologics and Biosimilars Manufacturers to debate best practices in upstream and downstream bioprocessing.
Frankfurt, Germany will host this bioprocessing-focused, knowledge-sharing conference to provide regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how. We have an agenda built around success stories from Europe's biopharmas as well as the technical expertise from International Biopharmas and BIG Pharmas, presentations on the latest manufacturing technologies such as single-use and end-to-end continuous processing for biologics, today’s challenges and opportunities in biomanufacturing, advances in upstream process development, cost-optimization strategies in downstream processing, analytical characterization strategies, facility design, and scale-up strategy, fill & finish innovation to streamline the operations amongst other crucial themes.
Biologics Manufacturing Europe 2023
Europe’s Biologics Manufacturing Challenges and Opportunities
The biologics manufacturing industry in Europe is rapidly expanding to meet the market’s demands for biologics. As a result, the industry is facing challenges in manufacturing capacity and increasing operational costs. There is a need for more efficient and larger-scale manufacturing facilities is becoming increasingly pressing. Many biologics companies are looking to expand their operations, but they are limited by the availability of qualified personnel and manufacturing infrastructure
Upstream Processing: Large-Scale Cell Line Development & Engineering
Large-scale cell line development and engineering is an integral part of upstream processing and can help ensure the successful production of biopharmaceuticals. The selection, characterisation and optimisation of cell lines for large-scale production ensures that products are manufactured in an efficient and cost-effective manner.
Upstream Processing: Cell Culture Development and Manufacturing
Cell culture development and manufacturing is used to produce high-quality proteins and monoclonal antibodies for use in medical treatments, as well as for research and development. It is crucial in the production of cell & gene therapy products, such as stem cell treatments and gene therapies. Cell culture development and manufacturing is a key component of the biopharmaceutical industry and will continue to be an important part of the development of new treatments.
Analytics & Quality: Method Validation of Bioanalytical & Quality-by-Design
Method validation of bioanalytical and Quality-by-Design (QbD) are important to ensure that the analytical methods used to measure the quality of a drug product are accurate, reliable and reproducible. Proper validation of analytical methods is essential for drug safety, efficacy and quality assurance. Additionally, validation of analytical methods helps to ensure that data used to make decisions regarding the production, marketing and distribution of a drug product is valid and reliable.
Downstream Processing: Late-Stage Process Development & Viral Clearance
Late-stage process development and viral clearance are important steps in the development of biopharmaceutical products. Process development activities focus on the optimization of production processes to ensure that the final product meets all quality and safety requirements. Viral clearance involves the removal of any potential contaminants from the product during manufacturing. These processes are critical for ensuring that biopharmaceutical products are safe, effective, and of high quality.
Downstream Processing: Product Concentration & Product Purification by Chromatography
Product concentration and product purification by chromatography manufacturing are two important processes in the biopharmaceutical industry. In product concentration, chromatography is used to separate a mixture of compounds into its individual components. The components are then isolated and concentrated to produce a desired result. In product purification, chromatography is used to remove impurities from a product.These processes are necessary to achieve a desired level of potency and purity of the product.
Formulation and Aseptic Fill & Finish Packaging: Fill - Finish Innovation to Streamline Operations
Formulation and aseptic fill & finish packaging are critical components in manufacturing pharmaceutical products. There is a need to balance the cost and performance of the finished product with the development of a new formulation that meets the safety and efficacy standards of the drug. In order to streamline operations, manufacturers have been implementing innovative technologies and techniques to optimise cost while also improving performance of aseptic fill & finish packaging.
Emerging Technologies and Applications: Novel Therapeutics Modalities
Novel therapeutics modalities are technologies and applications that utilize new methods and approaches for treating diseases and medical conditions.These modalities are currently being used to develop more effective and personalized treatments for a broad range of diseases and health conditions including cancer, cardiovascular diseases, neurodegenerative diseases, and infectious diseases.
2023 Sponsors
Exhibitor
Exhibitor
Technology Showcase Sponsor
Past #BME22 Sponsors & Exhibitors
Gold Sponsor
Silver Sponsor
Associate Sponsor
CMO Showcase Sponsor
Advertiser
Catch The Limited Super Access In Time To Save BIG!
Service & Solution Providers
Limited Special 1730 GBP (ends 07/04/23)
- Early Bird 1860 GBP (ends 05/05/23)
- Standard Rate 1920 GBP
Biopharma Based in EU
Limited Special 810 GBP (ends 07/04/23)
- Early Bird 930 GBP (ends 05/05/23)
- Standard Rate 1050 GBP
Big Pharma & Biopharma Based outside EU
Limited Special 930 GBP (ends 07/04/23)
- Early Bird 1175 GBP (ends 05/05/23)
- Standard Rate 1290 GBP
Event Materials
CDMO Geographical Distribution Infographic
It was great to attend the session physically, and have some exchange with industry players and exchange ideas. Thanks IMAPAC for great organisation!
Sanofi
KOH WEI JET, EVF Project Process Manufacturing Leader
Great forum for face to face interactions and for exchange of ideas and information.
WuXi Biologics
Chris Lee, Site Head, Singapore Development and Manufacturing
A well organized ambitious meeting. I hope it will continue to develop in the future.
GSK Vaccines
Jean-Francois Dierick, Strategic Analytical Validation and Lifecycle Lead, Analytical Research and Development
This conference was long overdue in Singapore and critical to making sure that CCT understands current challenges facing our Asian based clients. This allows us to quickly provide new or turn-key solutions and products that meet their needs.
Cold Chain Technologies
Regional Commercial Director
BMA 2022 was an excellently organised event and as a sponsor, participating was very valuable in meeting new connections and engaging with existing customers & contacts. I would recommend anyone involved in the regional biologics industry to participate in the event.
MasterControl
Ciaran O'Keeffe, Director, Business Development & Channel Sales
With the many restrictions and the need to hold the event onsite and online, I do think this event is well planned and held. Easy registration. Spacious, simple and professional settings. All the staffs are very friendly and helpful too. Thank you!
West Pharmaceutical Services
Sr. Technical Account Specialist
Bioworkshops appreciate the effort IMAPAC invested to restore a strong In-person participation to this hybrid event, bringing together many of the biologics manufacturing leaders from Asia along and global experts.
Bioworkshops Limited
Nick Kotlarski, President, VP of BioManufacturing
